CIK 0001999480 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Alto Neuroscience, Inc.
Sign in to watch- Ticker
- ANRO
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 834210124
- Phone
- 773-255-5012
- Business address
- 650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW, CA, 94041
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,567,247
- in 1 filing
Net −$3,567,247. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-06 | York Gwill Director | Conversion · Series A Preferred Stock | −53,196 | 0 | ||
| 2024-02-06 | Smith Nicholas Conrad CHIEF FINANCIAL OFFICER | Purchase | +1,563 | $16.00 | $25K | 1,563 |
| 2024-02-06 | Cox Christopher Nixon Director | Conversion | +588,898 | 588,898 | ||
| 2024-02-06 | Cox Christopher Nixon Director | Conversion | +126,755 | 715,653 | ||
| 2024-02-06 | Cox Christopher Nixon Director | Conversion · Series B Preferred Stock | −1,250,000 | 0 | ||
| 2024-02-06 | Cox Christopher Nixon Director | Conversion · Series C Preferred Stock | −281,917 | 0 | ||
| 2024-02-06 | Savitz Adam CHIEF MEDICAL OFFICER | Conversion | +7,851 | 7,851 | ||
| 2024-02-06 | Savitz Adam CHIEF MEDICAL OFFICER | Purchase | +17,000 | $16.00 | $272K | 24,851 |
| 2024-02-06 | Savitz Adam CHIEF MEDICAL OFFICER | Conversion · Series B Preferred Stock | −16,666 | 0 | ||
| 2024-02-06 | Etkin Amit PRESIDENT AND CEO | Conversion | +11,777 | 1,202,340 | ||
| 2024-02-06 | Etkin Amit PRESIDENT AND CEO | Purchase | +3,125 | $16.00 | $50K | 1,205,465 |
| 2024-02-06 | Etkin Amit PRESIDENT AND CEO | Conversion · Series B Preferred Stock | −25,000 | 0 | ||
| 2024-02-06 | Chen Po Yu (Jeff) Director | Conversion | +39,259 | 39,259 | ||
| 2024-02-06 | Chen Po Yu (Jeff) Director | Conversion | +8,450 | 47,709 | ||
| 2024-02-06 | Chen Po Yu (Jeff) Director | Conversion · Series B Preferred Stock | −83,333 | 0 | ||
| 2024-02-06 | Chen Po Yu (Jeff) Director | Conversion · Series C Preferred Stock | −18,794 | 0 | ||
| 2024-02-01 | York Gwill Director | Grant or award · Stock Option (right to buy) | +30,574 | 30,574 | ||
| 2024-02-01 | York Gwill Director | Grant or award · Stock Option (right to buy) | +3,083 | $11.88 | $37K | 3,083 |
| 2024-02-01 | Manji Husseini Director | Grant or award · Stock Option (right to buy) | +30,574 | 30,574 | ||
| 2024-02-01 | Manji Husseini Director | Grant or award · Stock Option (right to buy) | +3,083 | $11.88 | $37K | 3,083 |
Page 6 of 7 · 125 trades